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Background: Smoking cessation is a high-priority intervention to prevent CVD events and deaths in developing
countries. While several interventions to stop smoking have been proved successful, the question of how to
increase their effectiveness and practicality in developing countries remains. In this study, a newly devised
evidence-based smoking cessation service package will be compared with the existing service in a randomized
controlled trial within the community setting of Thailand.
Method/Design: This randomized control trial will recruit 440 current smokers at CVD risk because of being
diabetic and/or hypertensive. Informed, consented participants will be randomly allocated into the new service-
package arm and the routine service arm. The study will take place in the non-communicable disease clinics of
the Maetha District Hospital, Lampang, northern Thailand. The new smoking-cessation service-package comprises
(1) regular patient motivation and coaching from the same primary care nurse over a 3-month period; (2) monthly
application of piCO + smokerlyzer to sustain motivation of smoker’s quitting attempt and provide positive feedback
over a 3-month period; (3) assistance by an assigned family member; (4) nicotine replacement chewing gum to
relieve withdrawal symptoms. This new service will be compared with the traditional routine service comprising the
5A approach in a 1-year follow-up. Participants who consent to participate in the study but refuse to attempt
quitting smoking will be allocated to the non-randomized arm, where they will be just followed up and monitored.
Primary outcome of the study is smoking cessation rate at 1-year follow-up proven by breath analysis measuring
(Continued on next page)* Correspondence: myo@juntendo.ac.jp
1Department of Public Health, Juntendo University School of Medicine,
Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan
2Boromrajonani College of Nursing Nakhon Lampang (BCNLP), Lampang,
Thailand
Full list of author information is available at the end of the article
© 2013 Aung et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Aung et al. Trials 2013, 14:419 Page 2 of 14
http://www.trialsjournal.com/content/14/1/419(Continued from previous page)
carbomonoxide in parts per million in expired air. Secondary outcomes are smoking cessation rate at the 6-month
follow-up, blood pressure and heart rate, CVD risk according to the Framingham general cardiovascular risk score,
CVD events and deaths at the 12-month follow-up, and the cost-effectiveness of the health service packages.
Intention-to-treat analysis will be followed. Factors influencing smoking cessation will be analyzed by the structure
equation model.
Discussion: This multicomponent intervention, accessible at primary healthcare clinics, and focusing on the
individual as well as the family and social environment, is unique and expected to work effectively.
Trial registration: Current Controlled Trials ISRCTN89315117
Keywords: Smoking, Smokerlyzer, Family, Thailand, Lampang, CVD, Primary care, Tobacco, ESCAPE trialBackground
Cardiovascular diseases (CVDs) are the leading cause of
morbidity and mortality globally [1]. Developing coun-
tries such as Thailand are severely affected, and the
current trend is expected to get worse over the next few
decades [2,3]. Reducing the CVD burden via lifestyle
modification has, therefore, become an urgent public
health priority [1]. There are a number of modifiable risk
factors of CVDs such as smoking, physical inactivity and
unhealthy diet [4], and smoking cessation is considered
to have the greatest potential to prevent thousands of
CVD events and deaths [4].
Thailand is a middle-income developing country with
a current smoking rate of approximately 50% among
males and 5-6% among females [5,6]. The smoking rate
is heterogeneous across the country and could be as
high as 70% among both males and females in rural
areas of northern Thailand [7]. The increasing wave of
CVDs in recent years is seen as the primary cause of
hospitalization and rising numbers of CVD deaths
within all provinces of Thailand [8]. Thailand is a coun-
try with a strict tobacco control and an effective online
service for smokers attempting to give up smoking
[9,10]. However, previous surveys of tobacco use in
Thailand have revealed unique features of its smokers,
such as the high smoking rate in rural areas and high
prevalence of “roll-your-own” cigarettes and household
smoking [10]. A smoking cessation service reaching to
the primary health care is key to prevention of CVD in
Thailand. Enhancing the implementation of community-
based smoking cessation programs would avert the
health and economic burden of CVDs [10,11].
A randomized controlled trial, seeking an effective
smoking cessation service in the primary care setting of
developing countries, is very rare and has yet to be
conducted in Thailand [12]. While smoking cessation in-
terventions, such as brief counseling, nicotine replace-
ment and therapy, etc., were reported to be effective, the
question of how to increase their effectiveness and
practicality remains [11,13]. To function as part of pri-
mary health care, a culturally-tailored smoking cessationservice, which is feasible within the individual, social and
financial capitals of the target setting, is a necessity. In
this study, a newly devised evidence-based smoking ces-
sation service package will be compared, in a random-
ized controlled trial, with the existing service within the
community setting of northern Thailand.
Methods/Design
Study hypothesis
A smoking cessation service package comprising con-
tinuous motivation by a single designated nurse, ap-
plication of a smokerlyzer, continuous family support
and nicotine replacement therapy, based on individual
need, will lead to a more successful behavioral change
in patients at risk from cardiovascular diseases, as
compared to the conventional smoking-cessation ser-
vice [14].
Study objectives
The primary objective is to compare the smoking cessa-
tion rate between a new evidence-based smoking cessa-
tion service package and the conventional 5 A approach
to smoking cessation at the 1-year follow-up.
The secondary objectives are:
1. to compare the smoking cessation rate at the
6-month follow-up.
2. to compare the CVD risk by Framingham general
cardiovascular risk score among intervention and
control groups at the 1-year follow-up.
3. to determine the characteristics of those who have
successfully given up smoking and the determinants
of behavioral change.
4. to determine the characteristics of relapse smokers
after 6 months of cessation and the determinants of
behavioral change.
5. to compare the cardiovascular disease events
between ex-smokers, reduced smokers and continu-
ous smokers at the 1-year follow-up.
6. to determine the cost-effectiveness of the new
smoking cessation service package.
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The study design is essentially that of a randomized con-
trolled trial (RCT) comparing two parallel groups. How-
ever, given the nature of smoking cessation research, an
additional, third arm will be included for smokers who
refuse to try to give up smoking and so are unable to be
randomized into either of the treatment service arms.
Consequently, it will be a randomized, controlled trial
with an additional non-randomized arm. The study flow
chart is as follows.
Study site
Thailand is the study site. Maetha Hospital (MH) is the
leading center in this trial. The study will be imple-
mented via the MH network of mobile NCD clinics at
seven primary care units (PCU) within the Maetha dis-
trict. Study site PCUs were chosen based on the eligibil-
ity criteria of (1) the presence a regular mobile NCD
clinic; (2) a smoking rate among NCD clinic attendants
not less than 10%; (3) willingness of the PCU to join the
study.
Study population
The study population will comprise smokers with a high
CVD risk, having either hypertension or diabetes, or
both.
Eligibility criteria for individual patients to enroll in the
study
The selection of participants will be based on the follow-
ing inclusion and exclusion criteria:
Inclusion criteria
1. Current smokers with diabetes.
2. Current smokers with hypertension.
3. Current smokers with both diabetes and
hypertension.
4. Smokers who have never succeeded in giving up
smoking.
5. Male or female.
6. Aged 35–80 years.
Exclusion criteria
1. Any female patients who are pregnant or planning
to become pregnant.
2. Patients aged younger than 35 years.
3. Patients with documented type I diabetes.
4. Patients with cancer.
5. Patients with severe chronic pulmonary diseases
using home oxygen therapy.
6. Patients with a known diagnosis of a previous
cardiovascular disease (CVD) event.Ethical approval
Ethical approval of the study protocol was granted by the
Juntendo University Ethics Committee, Japan, by permis-
sion no. 2012194, and the Institutional Review Board at
Boromarajonani College of Nursing, Lampang, Thailand, by
approval number E2556/005. The study has been registered
as an international current control trial at the ISRCTN
registry. The ISRCTN registration no. ISRCTN89315117
was assigned on 9 July 2013 [14] Acronym of the study is
ESCAPE: Effective Smoking Cessation Augmented PackagE.
Written informed consent will be requested from eli-
gible individuals. Participants can freely decide to par-
ticipate in the trial after being informed about the study
(Autonomy). There are no racial or ethnical criteria for
inclusion in the study (Equity). Participants in each arm
of the study will receive routine health services, and
those in the new-service intervention arm will receive
some trial-related service benefits, such as breath ana-
lysis by smokerlyzer and provision of nicotine replace-
ment therapy if suffering from nicotine withdrawal.
There will be no or minimal introduction of risk to the
participants but instead an expected CVD risk reduction
via the smoking cessation intervention and study-related
health education (Beneficence).
Enrollment and randomization
To ensure the required sample size, smoking prevalence
among diabetes and hypertension clinics attendants was
surveyed. The study site is within the community setting
and coupling with non-communicable disease (NCD)
clinics, which is expected to promote the smoker’s ac-
cess to enrollment in the study. Those meeting eligibility
criteria will be invited to participate in the study in their
routine visit to the PCU. The participants who consent
and decide to attempt to stop smoking will be randomly
allocated into either the routine service intervention arm
or the new service intervention arm. Those who refuse
to attempt quitting smoking will be recruited to the
non-randomized arm (Figure 1). The randomization site
is the NCD clinic at the PCU. Randomization is blocked
with the center as a stratum. Random sequences are
generated by the statistician on the basis of blocks of 24.
The allocated arm for each participant will be provided
to the study sites PCUs in opaque, sealed envelopes.
Concealment of allocation
Requesting of consent and randomization will precede
explanations to patients about the procedures within
their allocated study arm. The allocated arm will be
revealed to the patient when the research nurse opens
the sealed envelope following recruitment, consent and
the participant’s agreement to attempt to give up smok-
ing. Participants will know the details only of the study
arm to which he/she has been randomly allocated. The
Smokers attending NCD clinics of 
Mae Tha hospital
Eligibility Criteria 
-Smokers at CVD risk through being 
diabetic and /or hypertensive 
-Willing to participate in the study
440 Smoking patients
164 allocated in
Routine service 5A 
1. Assertive communication between primary 
care nurse and patient (1st,2ndand 3rdmonth  
visits)
2. Smokerlyzer (1st,2ndand 3rdmonth visits)
3. Family member’s support and monitoring
4.NRT (chewing gum to those who need to  
relieve the nicotine withdrawal symptoms
1. Counseling in  
routine approach at 
enrollment one time  
2. Questionnaires 
Follow up for 12 months
164 allocated in intervention new service 
package
112 smokers




Follow up for 12 months
Randomization
328 smokers 
Breath analysis by Smokerlyzer: CO measurement in expired air 
Self –reported quitting rate, CVD event, CVD risk by Framingham scoring, 
Follow up for 12 months
Figure 1 Flow chart for enrollment and follow-up plan for RCT with an additional non-randomized arm. Note: *Fagerstrom nicotine
dependence test, NRT nicotine replacement therapy. Bold arrows show the randomized trial, and the dotted arrow shows the non-randomized arm.
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arm a participant will be allocated.Blinding
Double blinding is not possible because of the nature of
trials for health care service intervention. The PCU
nurse will know the intervention arms. However, pos-
sible investigator’s bias will be minimized, and anticipa-
tion of the allocated arm will be prevented by the block
randomization procedure [15].Intervention
An evidence-based smoking cessation intervention pack-
age was devised in order to represent a practical and
replicable smoking cessation service in the primary
health care setting of a developing country. The other
arm of the randomized control trial represents the con-
ventional smoking cessation service used in Thailand
(Table 1).New evidence-based service (intervention arm)
The new evidence-based service package arm will com-
prise the following interventions [14]: (1) during the first
meeting, a primary care unit (PCU) nurse will motivate
the patient to give up smoking by providing a clear ex-
planation, and the same nurse will provide repeated
advice each month for the next 3 months; (2) a piCO +
smokerlyzer will be used to show the level of carbon
monoxide (CO) the patient breathes out and the im-
provement of the patient’s lung health over 3 successive
months; (3) a PCU nurse will train one member of the
patient’s family on how to care for the patient until he/
she has successfully given up smoking; (4) patients who
suffer from nicotine craving are given nicotine replace-
ment chewing gum.
The existing service arm (control arm of the randomized
control trial)
The routine health service smoking cessation package
will include the following: (1) during the first meeting
Table 1 Timetable of interventions in the randomized controlled trial and additional non-randomized arm of the
ESCAPE study
Intervention
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13
Month 0 1 2 3 4 5 6 7 8 9 10 11 12
New package service
Assertive communication x x x x
Nicotine replacement chewing gum
to those indicating need
± ± ± ± ± ± ±
Family member assistance x x x x x x x x x x x x x
Smokerlyzer as motivational tool x x x
Existing service
Health care worker counseling
patient at enrollment
x
Routine 5 A service including assessment
of nicotine dependence questionnaires
x
Advice and encouragement on
NCD clinic follow-up visits
x x x
Refusing to give up smoking
Recruitment x
± shows the intervention to those who have indicated a need for nicotine replacement therapy.
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how to stop smoking; (2) the patient answers questions
about their smoking habit to indicate their level of nico-
tine dependency; (3) the patient is reminded by the
healthcare worker on subsequent visits to the hospital
how to stop smoking; (4) the patient is asked to let the
healthcare worker know if and when he/she has success-
fully been able to give up smoking.
Difference between two service arms
The two service arms differ in several components
(Table 1). In the new service arm, nursing intervention
is an assertive communication between a patient and
nurse to achieve the goal of stopping smoking rather
than conventional patient counseling by the nurse or
any health care staff as would be the case for routine
arm group [16]. The PCU nurse will ask the patient
what he/she knows about the risks of smoking and will
provide education about them. Then an assertive form
of communication will be established between the nurse
and patient assisting in the patient’s attempt to give up
smoking. The same PCU nurse will sustain such com-
munication, along with the implementation of an action
plan, for a period of 3 months after enrollment. This
communication may include phone calls to the partici-
pant and his/her family.
Second, participants in the new service arm group will
be able to see both the level of their nicotine depend-
ence, via the colored diode light in the smokerlyzer
breath analysis, and also the level of CO in their expired
air, as compared to their questionnaire rating as wouldbe the case for the routine arm group. This will provide
both visible positive feedback and an achievable goal in
the assertive communication between the nurse and
patient.
Third, the most striking difference between the two
service packages is the assigning, in the new service arm,
of a family member to monitor, remind and motivate the
smoker until smoking cessation is successful. The family
member, trained by the PCU nurse, will be empowered
by using an attractive “quit-smoking diary” along with
three different colored stickers to record the participant’s
choice on smoking each day: smoking (red), NRT chew-
ing gum (blue) and non-smoking (white) (Figure 2). This
diary is expected to serve as a reminder to both the
smoker and the assisting family member.
Fourth, nicotine replacement chewing gum will be in-
cluded as one of the components in the new intervention
arm. Participants in this arm will receive NRT when they
have nicotine withdrawal symptoms [17,18]. A protocol
for the provision of NRT has been developed based on
Thailand’s Clinical Practice Guideline in Smoking Cessa-
tion [19]. NRT will be provided after screening for with-
drawal symptoms [17], confirmed by the Fagerstrom test,
or breath analysis by smokelyzer or Nicodep test, but only
to those willing to use NRT [18,20]. Due to these differ-
ences between the two intervention arms, contamination
between the two arms is expected to be low.
Non-randomized arm (refused to quit smoking)
Once participants have agreed and consented to partici-
pate in the trial, they will be asked whether they are
Figure 2 A record book in which the family member will record a smokers’ progress of smoking cessation.
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participant agrees to give up smoking, he/she will be
randomized into the evidence-based new service package
arm or the routine service package arm (Figure 1,
Table 1). If the participant refuses to attempt to give up
smoking, he/she will be automatically allocated to the
non-randomized arm. Participants in this arm will not
receive any active intervention for smoking cessation,
apart from the routine medical service for their existing
disease, such as diabetes and hypertension, provided
under the universal coverage system.
Duration of interventions
The duration of the new smoking cessation service pack-
age is as follows:
1. Persistent motivation and coaching by a designated
PCU nurse for a period of 3 months.
2. Monthly application of the piCO + smokerlyzer for a
period of 3 months.
3. Assistance by a trained family member (or health
care worker in cases of smokers living alone) for a
period of 12 months.
The duration of the routine smoking cessation service
package is as follows:
1. Counseling of the patient by a healthcare worker
during only the first meeting at the NCD clinic of
the PCU.
2. Reminding the smoker to stop smoking ad libitum on
successive visits for a period of 12 months. The
components of each service arm are shown in Table 1.
Manual and training
An operational manual for the smokerlyzer will be pre-
pared and provided to the study site PCUs. PCU nurseswill be trained in how to use smokerlyzers 2 months
prior to implementation. Details of the existing smoking
cessation service will be reviewed and structured so as
to represent the routine service arm in the study. A
protocol for nicotine replacement chewing gum will be
prepared by the team of researchers, director of Maetha
Hospital, physicians, nurses and pharmacists [19]. The




Smoking cessation is defined as the stopping of smoking
for a period of at least 6 months and confirmed by the
assessment of carbon monoxide (CO) in the smoker’s
expired air using a smokerlyzer.
Diabetes
Diabetes mellitus is defined as one of the following cri-
teria: HbA1C concentration of more than 6.5%, or fast-
ing blood glucose of more than 126 mg/dL at least
twice, or on the spot blood glucose level of more than
200 mg/dL at least once, simultaneously with 2-h post-
prandial blood glucose of more than 200 mg/dL or a his-
tory of taking oral hypoglycemic drugs.
Hypertension
Hypertension is defined as (1) a systolic blood pressure
(SBP) of ≥140 mmHg or a diastolic blood pressure (DBP)
of ≥90 mmHg in participants who are not taking antihy-
pertensive medication or (2) subjects who are taking medi-
cation for hypertension.
Cardiovascular disease (CVD) events
Myocardial infarction, coronary insufficiency, unstable
angina, ischemic stroke, hemorrhagic stroke, transient
ischemic attack (TIA), peripheral artery disease or heart
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Patients with a known diagnosis of CVD will be
screened and excluded.CVD mortality
This is defined as any documented death caused by
CVD during the study period.Study outcome and outcome measurements
Primary outcome
The primary outcome of the study is the smoking cessa-
tion rate at the 1-year follow-up, proven by measure-
ment of carbon monoxide in parts per million (ppmCO).Secondary outcomes
Secondary outcomes of the trial are:
1. Smoking cessation rate at the 6-month follow-up,
proven by measurement of (ppmCO).
2. CVD risk measured by the Framingham general
cardiovascular risk score at the 12-month follow-up.
3. Blood pressure and heart rate measured at the 6-
and 12-month follow-up.
4. Number of CVD events and deaths at the 12-month
follow-up.
5. Cost-effectiveness of the health service packages at
the 12-month follow-up.Outcome measurements
Smoking cessation
This would be assessed by self-reported quitting
confirmed by breath analysis of the level of carbon
monoxide (CO) in expired air. A piCO + Smokerly-
zer® [21] carbon monoxide monitor will be used for
this assessment on the first visit, and again on the
6- and 12-month visits. It is a clinically proven way
to determine the carbon monoxide level and easy to
use in primary care. In previous studies, the Smoke-
lyzer has been shown to have positive, predictive
values for detecting smoking, at more than 95%
[12,22]. It can also serve as a motivational tool for
giving up smoking. Nicotine dependence will be
assessed by the Fagerstrom Nicotine Dependence
Test and the Nicodep Test [18,20]. The self-reported
smoking cessation rate is ascertained by asking par-
ticipants the number of cigarettes smoked in the
preceding 24 h.Blood pressure
A clinical digital sphygmomanometer will be used for
serial measurement of blood pressure.CVD risk assessment
The CVD risk assessment will apply the general
Framingham general CVD risk profile for primary
healthcare [23,24]. Calculation of the Framingham CVD
risk (FMH) score requires information relating to age,
sex, blood pressure, diabetes status, smoking status and
BMI. The FMH score will be assessed at the baseline,
6- and 12-month visits.
Perceived family support
A scale measuring the perceived family support, suitable
for the study site setting, was not available yet. Two sec-
tions of qualitative inquiries using in-depth interviews
among smokers in the Maetha district identified the
construct items and afterwards were developed into a
scale to measure the smoker’s family support. The scale
will be validated in a pilot study of similar population.
Health economic assessment
Costs for providing and receiving two intervention ser-
vices will be estimated by interviewing the health and
administrative personnel at MH and the PCUs, as well
as the participants. The cost of providing the services
includes costs relating to materials, personnel and the
facility. The cost of receiving the services includes par-
ticipants’ time and transportation to the facility. The
cost of medical services for CVDs will also be estimated,
based on information from the available literature.
CVD events and death
Participants will be followed up by nurse-administered,
structured questionnaires at the 6- and 12-month visits,
ascertaining medical history, lifestyle and health-related
behaviors. During each questionnaire, participants will
be asked whether they have had a CVD event referred to
the community hospital; any reported CVD event will be
confirmed by reviewing the NCD network medical re-
cords [25].
Waist and hip circumference measurement
Waist and hip circumference will be measured at the
baseline, 6- and 12-month visits. Stretch-resistant, stand-
ard measuring tapes will be provided to nurses to per-
form the waist circumference and hip circumference
measurement. Waist circumference measurement will be
made at the approximate midpoint between the lower
margin of the last palpable rib and the top of the iliac
crest, at the end of normal expiration, according to the
WHO protocol [26]. The hip circumference will be mea-
sured around the widest portion of the buttocks [26].
Sample size
A total of 328 participants will be randomized to have
164 in the new service arm and 164 in the routine
Aung et al. Trials 2013, 14:419 Page 8 of 14
http://www.trialsjournal.com/content/14/1/419service arm. The sample size for the randomized con-
trolled trial was calculated to have a power of 80% and
95% confidence interval so as to show the difference in
primary and secondary outcomes, and the CVD inci-
dence between the new package arm and the routine
service arm. It was calculated using the power sample
size calculation of Stata version 11, based on the previ-
ous year’s smoking cessation rate at the MH (9%), and
the estimated cessation rate of the evidence-based pack-
age (24%). Additionally, the calculated sample size was
increased by 20% to compensate for loss to follow-up.
The sample size for the additional non-randomized
arm was calculated at a ratio of 1:3 compared to the
total size of the two intervention arms. The power of
90% and 95 percent confidence interval will suffice to
see the difference in CVD events between ex-smokers
and continuous smokers, assumed as 0.1 and 0.25. To-
tally the sample size is 440 participants.
Data collection and follow-up
Since ESCAPE is a lifestyle modification trial, it requires
the measuring of several outcomes and their biological
and social covariates. Careful data collection and a well-
designed case record form will be applied to avoid the
extremes of burden on participants and insufficient data.
Training, practice and revision of the case record form
will precede the data collection.
Baseline survey
The balance between an individual’s motivation to stop
smoking and his or her degree of dependence on ciga-
rettes determines successful smoking cessation [27].
Thus, those variables will be measured at the outset of
the study and at the end of the intervention. Participants
will be asked to provide information about their current
and past smoking status, such as the number and type
of cigarettes smoked, the time they have an urge to smoke
in the morning, the source of their cigarettes and details
of previous attempts to give up. Breath analysis by smo-
kerlyzer, the Fagerstrom Test for Nicotine Dependence
(FTND) and the Nicodep® Test will be applied in order to
assess the participant’s smoking status and nicotine de-
pendence [20]. The smoker’s motivation will be measured
by the Motivation to Stop Scale (MTSS), a single-item
measure composed of key motivational constructs vali-
dated by a previous population-based study [28].
Moreover, this trial is assembled to reveal the impact
of smoking cessation on the CVD risk among those
most at risk. Thus, the FMH score will be measured at
the outset of the study and at the end of the follow-up
[23,24]. Blood pressure, heart rate, blood glucose, lipid
profile, BMI, and waist and hip circumference will be
measured, and these data inputs will be used to provide
the FMH score [24]. The patient’s current medicationfor diabetes or hypertension will be recorded, as well as
their food preference (salty food, fatty food) and their
family history of smoking, including any known CVD
events or deaths.
The new evidence-based service intervention will
focus not only on the individual, but also on the social
environment of the individual, such as their family sup-
port. Thus, perceived family support will be measured at
the outset. Demographic and socioeconomic information
of the participants will also be collected, as well as infor-
mation regarding costs relating to travel, the provider,
client and health service. As a covariate, individual
health literacy will briefly be assessed. Measurement of
this latent variable will apply communicative and critical
health literacy assessment, developed and validated by
Ishikawa et al. [29].
Follow-up
The study outcome measurement and follow-up sched-
ule is detailed in Table 2. Several ideas to limit the miss-
ing data were followed in designing the ESCAPE trial
[30]. This trial will be undertaken following the routine
schedule of the NCD clinics to which diabetes and
hypertension patients make regular visits for medical
checkups and receiving drugs. Since the study popula-
tion is routinely served by the PCUs, the chance of
dropout is limited. Participants are regular and long-
term clients of PCU health services. The rapport be-
tween NCD patients and PCU nurses may strengthen
the follow-up and minimize the dropout in the trial.
Moreover, the intervention design is an add-on design
in which additional evidence-based components are
added to the existing routine service [30]. Regarding the
outcome measurement, most of the secondary outcomes
are feasible to measure via the routine data collection of
the study site hospital network. Furthermore, the sample
size has been increased by 20% to compensate for
dropouts.
The study is carefully designed randomized controlled
trial, evaluating two approaches of active intervention
and comparing the rate of behavior change. However,
the CVD outcome event rate of the active intervention
arms will also be analyzed and compared with that of
the non-randomized arm made up of smokers refusing
to try to give up smoking. It will require the adjustment
of minimal residual confounders. Moreover, there will be
different models of covariates used to analyze different
outcomes. For instance, adjustments in the comparison
of CVD events and deaths between the intervention and
control arms may include family history, lifestyle, phys-
ical activity, alcohol consumption, dietary habits, current
medications and socioeconomic status [25]. To assess
physical activity as a covariate, a rapid physical activity
assessment scale will be applied [31]. Therefore, possible
Table 2 Overview of data collection and measurements in all three arms of ESCAPE study
Follow-up
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13
Month 0 1 2 3 4 5 6 7 8 9 10 11 12
Inclusion and exclusion criteria x
Framingham scoring x x x
Self-reported smoking cessation x x x x
Smokerlyzer x x x
Fagerstrom Test x x x
Blood pressure x x x x x x x
BMI x x x x
Blood glucose x x x
Waist circumference x x x
Hip circumference x x x
HbA1C x
Lipid profile x
CVD event x x x
CVD death x x x
Questionnaires
Demography x
Questionnaire assessing motivation to stop smoking (MTSS) x x x
Questionnaire assessing cost effectiveness x x x
Questionnaire assessing family support on smoking cessation x x x
Questionnaire assessing health literacy x x x
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ately in later analysis [32] (Table 3).
The level of perceived family support and its impact
will vary among participants. Participants in the routine
service arm and the refusing to give up arm are not sup-
posed to receive care by a family member, purposefully
and systemically trained and empowered by the nurse.
However, a participant in the control arm may, by
chance, also receive strong family support. In view of
this major difference, the impact of family support
would be measured and adjusted statistically via multi-
variable analysis.
Analyses plan
All analyses for pre-specified outcomes in the trial
protocol will strictly follow the intention-to-treat
principle [33]. Statistical significance in all statistical
analysis will be taken as a P value less than 0.05 with a
95% confidence interval. Relative risk (RR) for achieving
primary outcome, smokerlyzer-confirmed smoking ces-
sation, will be reported with the 95% confidence interval.
Moreover, the number needed to treat (NNT) for
achieving smokerlyzer-confirmed smoking cessation by
the two intervention arms will be reported [34]. To over-
come the contamination of the intervention, complieraverage causal effect (CACE) analysis will necessarily be
applied.Smoking cessation rate
The Smokerlyzer-confirmed smoking cessation rate will
be compared between two arms of the RCT, at 6 months
and 12 months of follow-up, by applying the chi-square
test. The smoking cessation rate will also be compared
among the three arms of the study. The factors influen-
cing successful smoking cessation at 12 months will be
analyzed by multivariable regression model-adjusting co-
variates. Continuous variables, such as expired CO
levels, the Fagerstrom score and nicotine dependence
levels, will be compared using MANOVA.CVD risk, CVD events and CVD death
CVD risk via FMH scores, blood pressure, heart rate
and BMI will be compared between those successfully
giving up smoking and continuous smokers by adjusting
covariates. Moreover, the time event analysis approach
will be applied to compare the CVD events and CVD
deaths between the two intervention arms. Those out-
comes will then be analyzed among the three arms of
the study by applying the Cox regression model.
Table 3 Confounder measurements
Confounder Variables How to measure
Demographic characteristics Age, sex, social status, family size, educational
attainment, occupational history, income
Questionnaire
Lifestyle Alcohol consumption, physical activity Questionnaire
Genetic factor Family history of diabetes, hypertension and CVD Questionnaire
Drugs Different medications for diabetes and hypertension Clinical record
Health literacy [29] A scale of five questions Questionnaire of Ishikawa’s scale [29]
Family support A scale of 16 questions Questionnaire
Physical activity RAPA scale [30] Questionnaire
Figure 3 A path model of the smoking cessation behavior change hypothesis.
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The structure equation model will be used to determine
the factors influencing the behavioral change of patients
at risk of CVD to stop smoking (Figure 3). Individual
factors, such as age, sex, motivation to stop smoking and
health literacy; social factors, such as perceived family
support, income, household smoking prevalence and
residence address; health service factors, such as medica-
tions and NRT use; tobacco-related factors, such as the
number of cigarettes smoked, tobacco cost and cigarette
type; and disease conditions, such as hypertension, BMI,
diabetes and CVD risk on smoking cessation, will be an-
alyzed using a holistic approach.
Cost-effectiveness analysis
The cost of interventions will be compared in terms of
outcome achievement. The additional cost of producing
an additional percentage of successful quitters at 1-year
follow-up will be calculated. Based on the Framingham
general cardiovascular risk score, differences in CVD
events and deaths and the associated costs between the
arms will be estimated for a period of 10 years at the
end of the 1-year follow-up. Lifetime costs and health
outcomes for our study population (aged 35 years and
above) will be estimated using data both in and outside
Thailand. Outcomes of the analysis will be: CVD events
and deaths averted and cost over 10 years; incremental
cost-effectiveness ratio (ICER) per CVD death averted;
lifetime costs and quality-adjusted life years (QALYs)
gained; and ICER per QALYs gained. The analysis will
be performed using both the provider and societalFigure 4 A conceptual model of evidence-based interventions and th
stop smoking.perspective. All the future costs and outcomes will be
discounted at a rate of 3% per annum. Sensitivity ana-
lysis will be employed to check the robustness of the
results.
Qualitative analysis
The characteristics of a participant successfully giving
up smoking will be analyzed qualitatively as a positive
deviance.
Discussion
Smoking cessation is considered to be the most urgent
and high-priority intervention for prevention of non-
communicable disease crisis internationally [1]. WHO
estimated that 17.3 million people die of CVDs each
year, 80% of which take place in low- and middle-
income countries [4,10]. CVDs are preventable, and a
substantial number of CVD-related deaths can be pre-
vented by smoking cessation. Thailand, a middle-income
country, is witnessing a rise in smoking prevalence, espe-
cially among the male population, with significant health
and economic impacts [5,35,36]. Therefore, despite the
nationwide controls on tobacco, strengthening the
smoking cessation health service is an urgent necessity
in Thailand [35]. The ESCAPE study aims to fill this gap
by devising a multicomponent smoking-cessation service
applicable at the primary care level.
In considering the individualized needs of patients in
their attempts to give up smoking, a care approach pack-
age has been designed, the steps of which are outlined in
Figure 4.eir actions in the development of behavioral change to
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the motivation to give up smoking, such as motivational
interviewing or brief counseling, can increase the rate of
smoking cessation [37]. Having generated initial motiv-
ation to give up smoking, the challenge, in practice, is to
sustain this motivation [27,38] (Figure 4). Evidence con-
sistently states that the persistent offering of assistance,
medication or behavioral support with the aim of smok-
ing cessation is more effective than brief advice or a sin-
gle session of counseling [38]. Recently, the sustainable
impact of the nurse’s or allied healthcare worker’s empir-
ical assertive approach was reported to have had a posi-
tive effect on cardiovascular risk factors, including
smoking cessation [16]. Hence, this approach will be
used in the current study for the new service arm.
Nursing interventions increase the smoking cessation
rate, but the monitoring of smoking behavior remains a
challenge [37]. In this study, PCU nurses will use smo-
kerlyzers in the new service arm to monitor smokers’ at-
tempts to give up smoking. Breath analysis results will
be shown to participants, enabling them to see the de-
cline in the CO level of their expired air.
Pharmacological interventions, such as nicotine re-
placement therapy (NRT), have been shown to work ef-
fectively within developed settings [39]. NRT relieves
nicotine withdrawal symptoms and thus helps to sustain
motivation to stop smoking [40]. However, in the devel-
oping setting of Thailand, while NRT has passed safety
tests [41], the medication is not yet available via the
publically financed health service system. Moreover, re-
cent studies in Thailand heterogeneously reported that
smokers and healthcare providers resorted to locally
available herbs and remedies to relieve nicotine with-
drawal and tobacco craving symptoms [12,42]. Thus,
another challenge in designing an effective smoking ces-
sation service is to provide free medication at the pri-
mary health care level to relieve nicotine withdrawal
symptoms. Nicotine replacement chewing gum, there-
fore, will be included as one of the components in the
new intervention arm of the ESCAPE study. Its cost-
effectiveness will be analyzed with a view to replication
in similar developing country settings.
Next, the need for support and care may differ among
smokers (Figure 4); some patients may need motivation,
some may need relief from craving symptoms by nicotine
replacement therapy, and some may need buddy support
[38]. Close monitoring and the kind support provided by a
family member help smokers to succeed in giving up
smoking [38,43]. Moreover, public health intervention
aiming at lifestyle changes needs to focus on individual as
well as social and environmental influences. In consider-
ation of this, a component will be added to the new ser-
vice package, that of close monitoring and continual
support of the smoker by a family member (or otherassigned member) using a sticker record diary. Social sup-
port may empower the smoker in his/her attempts to give
up, while relieving the stigma of smoking that may be ex-
perienced by other family members [43].
Existing evidence suggests that a smoking cessation ser-
vice, delivered in combination with other health services,
might be a more effective approach than the conventional
delivery through tobacco clinics [44,45]. The ESCAPE
study is strategically designed to improve access to a
smoking cessation service within the community. In this
study, NCD clinics, regularly attended by patients at risk
of CVD, are chosen as the centers to provide the smoking
cessation service. Thus, smokers attempting to stop smok-
ing will have easy access to the health service within their
community. Moreover, this approach is expected to
strengthen the follow-up and minimize the dropout num-
ber of participants during the research.
In this study a smoking cessation intervention at the
primary health care level in the setting of northern
Thailand will be tested. The 5 A approach is currently
adopted by many hospitals in Thailand to treat smokers.
The existing systems used at the study sites and the
human resources available were observed. Based on
existing global evidence, a new smoking cessation inter-
vention package has been designed to treat smokers at
the primary health care level. Its efficacy will be assessed
by outcomes of behavioral change and cardiovascular
risk reduction, and the cost effectiveness of achieving
those outcomes. It is expected to generate a culturally
tailored, practically effective smoking cessation service




RCT: Randomized controlled trial; MH: Maetha hospital; PCU: Primary health
care unit; FMH score: General Framingham scoring; CVD: Cardiovascular
disease; SEM: Structural equation modeling; ICER: Incremental cost-
effectiveness ratio; QALY: Quality-adjusted life years.
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